Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118285) titled 'Research on precise intervention strategies for bone marrow suppression bleeding related to the treatment of malignant hematological diseases' on Feb. 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Xuancheng people's Hospital
Condition:
Thrombocytopenia associated with treatment of hematologic malignancies
Intervention:
Eltrombopag intervention group:Eltrombopag 75mg qd po for up to 2 weeks
rVIIa intervention group:rVIIa 70-90ug/kg once
no more than 3 times
Eltrombopag control group:Not suitable for platelet active drugs, such as IL-11, tpo-ra, TPO, etc
Recruitment Status: Rec...